Pfizer Inc. $PFE Stock Position Lessened by Commonwealth Retirement Investments LLC

Commonwealth Retirement Investments LLC decreased its position in Pfizer Inc. (NYSE:PFE) by 72.2% in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 7,579 shares of the biopharmaceutical company’s stock after selling 19,707 shares during the quarter. Commonwealth Retirement Investments LLC’s holdings in Pfizer were worth $189,000 at the end of the most recent reporting period.

Other institutional investors have also modified their holdings of the company. Horizon Financial Services LLC lifted its holdings in shares of Pfizer by 174.8% in the fourth quarter. Horizon Financial Services LLC now owns 1,014 shares of the biopharmaceutical company’s stock valued at $25,000 after buying an additional 645 shares during the period. Godfrey Financial Associates Inc. acquired a new stake in shares of Pfizer in the fourth quarter valued at $26,000. YANKCOM Partnership acquired a new stake in shares of Pfizer in the fourth quarter valued at $28,000. HFM Investment Advisors LLC lifted its holdings in shares of Pfizer by 61.0% in the fourth quarter. HFM Investment Advisors LLC now owns 1,127 shares of the biopharmaceutical company’s stock valued at $28,000 after buying an additional 427 shares during the period. Finally, Darwin Wealth Management LLC acquired a new stake in shares of Pfizer in the second quarter valued at $32,000. Institutional investors and hedge funds own 68.36% of the company’s stock.

More Pfizer News

Here are the key news stories impacting Pfizer this week:

• Positive Sentiment: Pfizer reported encouraging Phase 2b data for its once-monthly obesity drug, showing about 15.9% to 16% weight loss, reinforcing hopes that the company could become a more meaningful player in the fast-growing weight-loss market. Pfizer’s obesity drug shows 16% weight loss in phase 2b study
• Positive Sentiment: The U.S. FDA expanded approval of Pfizer’s HYMPAVZI for additional hemophilia A and B patient groups, including pediatric patients, which should widen the drug’s addressable market and support future sales growth. U.S. FDA Approves Pfizer’s HYMPAVZI for the Treatment of Two Additional Hemophilia A or B Patient Populations with Significant Medical Need
• Positive Sentiment: Unusually heavy call-option activity suggests traders are positioning for more upside in PFE, reflecting rising near-term optimism around the company’s pipeline news.
• Neutral Sentiment: Pfizer also presented at Goldman Sachs’ Global Healthcare Conference, but no major new strategic update was highlighted in the available summary. Pfizer Inc. (PFE) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript
• Negative Sentiment: Competition in obesity drugs remains intense, with another company reporting strong weight-loss results, reminding investors that Pfizer will need to keep delivering to compete in this high-profile market. Sciwind Reports 12.8% Weight Loss As Global Expansion Talks Deepen

Wall Street Analyst Weigh In

Several analysts have recently weighed in on PFE shares. Cantor Fitzgerald restated a “neutral” rating on shares of Pfizer in a report on Monday, June 1st. UBS Group restated a “neutral” rating and issued a $27.00 price objective on shares of Pfizer in a report on Wednesday, May 27th. Bank of America cut their price objective on Pfizer from $27.00 to $26.00 and set a “neutral” rating for the company in a report on Thursday, April 9th. Barclays started coverage on Pfizer in a report on Thursday, February 19th. They issued an “underweight” rating and a $25.00 price objective for the company. Finally, Daiwa Securities Group lowered Pfizer from an “outperform” rating to a “neutral” rating and set a $27.00 price objective for the company. in a report on Thursday, February 12th. One analyst has rated the stock with a Strong Buy rating, five have assigned a Buy rating, eleven have assigned a Hold rating and three have given a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock has an average rating of “Hold” and a consensus target price of $28.82.

Pfizer Trading Down 1.5%

NYSE:PFE opened at $25.66 on Tuesday. The company has a quick ratio of 0.94, a current ratio of 1.25 and a debt-to-equity ratio of 0.67. Pfizer Inc. has a 1-year low of $23.11 and a 1-year high of $28.75. The firm has a market capitalization of $146.22 billion, a price-to-earnings ratio of 19.58 and a beta of 0.34. The stock has a fifty day simple moving average of $26.59 and a 200 day simple moving average of $26.30.

Pfizer (NYSE:PFE) last released its quarterly earnings results on Tuesday, May 5th. The biopharmaceutical company reported $0.75 earnings per share for the quarter, beating analysts’ consensus estimates of $0.72 by $0.03. Pfizer had a return on equity of 19.44% and a net margin of 11.83%.The business had revenue of $14.45 billion during the quarter, compared to analyst estimates of $13.84 billion. During the same quarter last year, the company posted $0.92 EPS. Pfizer’s revenue for the quarter was up 5.4% on a year-over-year basis. Pfizer has set its FY 2026 guidance at 2.800-3.000 EPS. Sell-side analysts forecast that Pfizer Inc. will post 2.99 earnings per share for the current year.

Pfizer Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Friday, June 12th. Investors of record on Friday, May 8th will be given a $0.43 dividend. The ex-dividend date is Friday, May 8th. This represents a $1.72 dividend on an annualized basis and a dividend yield of 6.7%. Pfizer’s dividend payout ratio (DPR) is 131.30%.

Pfizer Company Profile

Pfizer Inc (NYSE: PFE) is a multinational biopharmaceutical company headquartered in New York City. Founded in 1849 by Charles Pfizer and Charles Erhart, the company researches, develops, manufactures and commercializes a broad range of medicines and vaccines for human health. Its activities span discovery research, clinical development, regulatory affairs, manufacturing and global commercial distribution across multiple therapeutic areas.

Pfizer’s portfolio and pipeline cover oncology, immunology, cardiology, endocrinology, rare diseases, hospital acute care and anti-infectives, along with a substantial vaccine business.